Sotalol hydrochloride - AltaThera Pharmaceuticals
Alternative Names: Sotalol IV- AltaThera PharmaceuticalsLatest Information Update: 21 Mar 2022
At a glance
- Originator Academic Pharmaceuticals
- Developer Academic Pharmaceuticals; AltaThera Pharamceuticals
- Class Antihypertensives; Class III antiarrhythmics; Ethanolamines; Small molecules
- Mechanism of Action Beta adrenergic receptor antagonists; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Atrial fibrillation; Ventricular arrhythmias
Most Recent Events
- 31 Dec 2021 Hyloris Pharmaceuticals initiates enrolment in a clinical trial for Atrial fibrillation and Ventricular arrhythmias (IV) before December 2021
- 17 Jun 2020 Launched for Atrial fibrillation in USA (IV) before June 2020
- 16 Mar 2020 AltaThera Pharmaceuticals has patent protection for sotalol IV in USA